Published in J Parkinsons Dis on January 01, 2011
Drp1 inhibition attenuates neurotoxicity and dopamine release deficits in vivo. Nat Commun (2014) 1.61
Deletion of caspase-8 in mouse myeloid cells blocks microglia pro-inflammatory activation and confers protection in MPTP neurodegeneration model. Aging (Albany NY) (2015) 0.81
Are striatal tyrosine hydroxylase interneurons dopaminergic? J Neurosci (2015) 0.81
Activation of ATP-sensitive potassium channels enhances DMT1-mediated iron uptake in SK-N-SH cells in vitro. Sci Rep (2016) 0.77
A novel biomechanical analysis of gait changes in the MPTP mouse model of Parkinson's disease. PeerJ (2015) 0.77
Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease. J Neurochem (2016) 0.77
Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors. Neuroscience (2016) 0.76
Nocardia asteroides-Induced movement abnormalities in mice: Relevance for Parkinson's disease? Mov Disord (2016) 0.75
Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress. PLoS One (2017) 0.75
TracMouse: A computer aided movement analysis script for the mouse inverted horizontal grid test. Sci Rep (2016) 0.75
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease. Mol Neurodegener (2016) 0.75
Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration. Nat Commun (2016) 0.75
Mild MPP(+) exposure-induced glucose starvation enhances autophagosome synthesis and impairs its degradation. Sci Rep (2017) 0.75
FosB and ΔFosB expression in brain regions containing differentially susceptible dopamine neurons following acute neurotoxicant exposure. Brain Res (2016) 0.75
ASIC1a Deficient Mice Show Unaltered Neurodegeneration in the Subacute MPTP Model of Parkinson Disease. PLoS One (2016) 0.75
Rethinking energy in parkinsonian motor symptoms: a potential role for neural metabolic deficits. Front Syst Neurosci (2015) 0.75
Deficiency in Neuronal TGF-β Signaling Leads to Nigrostriatal Degeneration and Activation of TGF-β Signaling Protects against MPTP Neurotoxicity in Mice. J Neurosci (2017) 0.75
Neuroprotective Effect and Mechanism of Thiazolidinedione on Dopaminergic Neurons In Vivo and In Vitro in Parkinson's Disease. PPAR Res (2017) 0.75
Mitochondria-Derived Damage-Associated Molecular Patterns in Neurodegeneration. Front Immunol (2017) 0.75
Behavioral Phenotyping and Pathological Indicators of Parkinson's Disease in C. elegans Models. Front Genet (2017) 0.75
Epigallocatechin Gallate Has a Neurorescue Effect in a Mouse Model of Parkinson Disease. J Nutr (2017) 0.75
CIB1 protects against MPTP-induced neurotoxicity through inhibiting ASK1. Sci Rep (2017) 0.75
Parkinson's disease: mechanisms and models. Neuron (2003) 14.84
Molecular characterization of mitochondrial apoptosis-inducing factor. Nature (1999) 14.41
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci (2007) 11.24
Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci (2000) 10.62
Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science (2002) 8.41
Molecular pathways of neurodegeneration in Parkinson's disease. Science (2003) 7.55
Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol (2004) 6.14
Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature (2001) 5.07
Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell (1998) 5.06
'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature (2007) 5.03
Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med (1999) 4.88
Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron (2001) 4.43
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci (2002) 4.38
Reactive oxygen species and the central nervous system. J Neurochem (1992) 4.27
Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science (1994) 3.86
Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol (1999) 3.63
Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem (2002) 3.14
Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc (2007) 3.00
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.95
Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol (1992) 2.92
Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration (1995) 2.71
Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci (1985) 2.70
Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature (1995) 2.69
Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J (2000) 2.65
Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res (1979) 2.61
Cytotoxicity of microglia. Glia (1993) 2.29
Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol (1996) 2.22
Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther (2000) 2.14
Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med (1996) 2.14
Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol (2003) 2.14
Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci U S A (2005) 2.13
Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochem Soc Trans (1993) 2.10
Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci U S A (1996) 2.10
In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience (1997) 2.07
The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J Neurosci (2000) 2.07
Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience (1996) 2.06
Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res (1999) 2.02
Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci (2002) 1.96
Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience (2001) 1.96
Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature (1991) 1.94
Nifedipine- and omega-conotoxin-sensitive Ca2+ conductances in guinea-pig substantia nigra pars compacta neurones. J Physiol (1993) 1.90
Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci U S A (1999) 1.88
Biomedicine. Parkinson's--divergent causes, convergent mechanisms. Science (2004) 1.87
Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. J Biol Chem (1998) 1.84
Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci (1992) 1.79
Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem (2000) 1.78
Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci (2003) 1.73
Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science (1984) 1.72
Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res (1984) 1.71
Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res (1988) 1.71
Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci U S A (2005) 1.68
Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J Neurosci (2001) 1.64
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem (2002) 1.61
The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol (1999) 1.59
Indirect mutagenesis by oxidative DNA damage: formation of the pyrimidopurinone adduct of deoxyguanosine by base propenal. Proc Natl Acad Sci U S A (1998) 1.57
Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res (1991) 1.55
Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem (1998) 1.52
Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci (2001) 1.52
Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem (2000) 1.49
Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov Disord (2006) 1.49
Animal models of Parkinson's disease progression. Acta Neuropathol (2008) 1.49
Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm (Vienna) (1996) 1.45
Nitric oxide neurotoxicity. J Chem Neuroanat (1996) 1.39
Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res (2002) 1.38
Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke? Acta Neurol Scand Suppl (1989) 1.37
Mechanisms of MPTP toxicity. Mov Disord (1998) 1.35
MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet (2000) 1.34
Oxidative stress: free radical production in neural degeneration. Pharmacol Ther (1994) 1.33
Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem (1997) 1.32
A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol (1985) 1.30
An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc (1997) 1.26
Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations. Adv Neurol (1993) 1.25
Dopaminergic cell death induced by MPP(+), oxidant and specific neurotoxicants shares the common molecular mechanism. J Neurochem (2001) 1.24
The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta (1999) 1.23
Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones. Br J Pharmacol (1994) 1.22
The microglial cell. A historical review. J Neurol Sci (1995) 1.22
The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci (2000) 1.22
The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration (1996) 1.20
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci (1998) 1.14
Minocycline enhances MPTP toxicity to dopaminergic neurons. J Neurosci Res (2003) 1.13
Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+). Exp Neurol (2006) 1.12
Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol Behav (2009) 1.11
An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A (2001) 1.11
Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J Neurochem (1991) 1.08
Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci (2004) 1.07
Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Exp Neurol (1994) 1.04
Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. Exp Neurol (2009) 1.04
Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions. J Neurochem (2009) 1.03
The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol (1986) 1.01
Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res (1987) 1.00
Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Neuroscience (2006) 1.00
Implication of poly (ADP-ribose) polymerase (PARP) in neurodegeneration and brain energy metabolism. Decreases in mouse brain NAD+ and ATP caused by MPTP are prevented by the PARP inhibitor benzamide. Ann N Y Acad Sci (1999) 0.98
Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurones in the mouse. J Neurochem (1985) 0.98
Decreases in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide. Brain Res (1998) 0.98
Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism. Exp Neurol (2009) 0.97
Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J (1998) 0.96
MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse (1994) 0.96
Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport (1995) 0.95
Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci (1986) 0.95
Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology (2004) 2.50
Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology (2005) 2.24
Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur J Neurosci (2005) 1.70
The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. J Lipid Res (2004) 1.52
Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J Pharmacol Exp Ther (2003) 1.25
The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol (2003) 1.22
Anandamide content and interaction of endocannabinoid/GABA modulatory effects in the NTS on baroreflex-evoked sympathoinhibition. Am J Physiol Heart Circ Physiol (2003) 1.20
Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses. J Neurosci (2013) 1.06
Increased synapses in the medial prefrontal cortex are associated with repeated amphetamine administration. Synapse (2009) 0.90
Advances in thin tissue Golgi-Cox impregnation: fast, reliable methods for multi-assay analyses in rodent and non-human primate brain. J Neurosci Methods (2013) 0.85
Retrieval of contextual memories increases activity-regulated cytoskeleton-associated protein in the amygdala and hippocampus. Brain Struct Funct (2012) 0.80
Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian Striatum. Basal Ganglia (2012) 0.76